HN30 Stock Chart & Stats
€0.05
€0.00(0.00%)
At close: 4:00 PM EDT
€0.05
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.03 - €0.08
Previous CloseN/A
Volume0.00
Average Volume (3M)588.00
Market Cap
€3.21M
Enterprise Value€2.50M
Total Cash (Recent Filing)€1.19M
Total Debt (Recent Filing)€354.09K
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding61,077,354
10 Day Avg. Volume0
30 Day Avg. Volume588
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)3.29
Price to Sales (P/S)0.00
P/FCF Ratio-5.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Equity Position (2025)The shift to positive equity and modest leverage in 2025 materially improves financial flexibility versus prior years. This durable improvement lowers insolvency risk, increases ability to raise capital or partner, and supports continued R&D investment over the medium term.
Rebuilding Asset BaseA meaningful rebuild of total assets provides a stronger operational foundation and tangible resources to support product development or licensing. Sustained asset levels enhance strategic optionality and reduce the firm's fragility during extended development cycles.
Improving Cash Outflow TrendA reduction in cash burn versus the trough years signals better cost control and operational discipline. While cash flow remains negative, a durable downward trend in outflows eases near-term financing pressure and lengthens runway for executing strategy or securing partnerships.
Bears Say
No Recurring RevenueAn absence of recurring revenue across multiple years means the business lacks a proven commercial engine. This structural revenue void forces reliance on financing or one‑offs, making long‑term viability dependent on successful product commercialization or external capital.
Persistent Negative Cash FlowConsistent negative operating and free cash flow demonstrates ongoing cash burn and an inability to self‑fund operations. Over months this necessitates repeated external financing, which can dilute shareholders and constrain strategic investments if capital markets tighten.
Historical Volatile / Negative EquityEpisodes of negative equity in 2023–2024 signal prior solvency stress and weaken creditor and partner confidence. Even with 2025 improvement, historical volatility can limit access to favorable financing, impose covenant risks, and hinder long‑term strategic commitments.
Restart Life Sciences News
HN30 FAQ
What was Restart Life Sciences’s price range in the past 12 months?
Restart Life Sciences lowest stock price was €0.03 and its highest was €0.08 in the past 12 months.
What is Restart Life Sciences’s market cap?
Restart Life Sciences’s market cap is €3.21M.
When is Restart Life Sciences’s upcoming earnings report date?
Restart Life Sciences’s upcoming earnings report date is Aug 21, 2026 which is in 15 days.
How were Restart Life Sciences’s earnings last quarter?
Currently, no data Available
Is Restart Life Sciences overvalued?
According to Wall Street analysts Restart Life Sciences’s price is currently Overvalued.
Does Restart Life Sciences pay dividends?
Restart Life Sciences does not currently pay dividends.
What is Restart Life Sciences’s EPS estimate?
Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Restart Life Sciences have?
Restart Life Sciences has 61,077,354 shares outstanding.
What happened to Restart Life Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Restart Life Sciences?
Currently, no hedge funds are holding shares in DE:HN30
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Restart Life Sciences
Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.